• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

清零 COVID-19。

Zeroing out on zero-COVID.

机构信息

William C. Kirby is the T.M. Chang Professor of China Studies and the Spangler Family Professor of Business Administration at Harvard University, Cambridge, MA, USA.

出版信息

Science. 2022 Jun 3;376(6597):1026. doi: 10.1126/science.add1891. Epub 2022 Jun 2.

DOI:10.1126/science.add1891
PMID:35653468
Abstract

There is no such thing as "zero-COVID." As the Omicron variant spreads to China's capital city, Beijing, the question is not if, but when and how, China will begin to "live with COVID-19" rather than continue to impose endless lockdowns. The problem is that under China's stifling political climate, this notion cannot be uttered, let alone debated. How did a country with a history of deep respect for science and a laser focus on becoming a global powerhouse in technology and innovation fall into such isolation from the rest of the world?

摘要

没有“零新冠”这回事。随着奥密克戎变异株在中国首都北京的传播,问题不是中国是否会开始“与新冠共存”,而是何时以及如何开始,而不是继续实施无休止的封锁。问题在于,在中国令人窒息的政治氛围下,这个概念不能被提及,更遑论争论。一个历史上深以科学为尊、专注于成为科技和创新全球强国的国家,怎么会与世界其他国家如此隔绝?

相似文献

1
Zeroing out on zero-COVID.清零 COVID-19。
Science. 2022 Jun 3;376(6597):1026. doi: 10.1126/science.add1891. Epub 2022 Jun 2.
2
Estimating the transmission dynamics of SARS-CoV-2 Omicron BF.7 in Beijing after adjustment of the zero-COVID policy in November-December 2022.估算 2022 年 11 月-12 月北京调整“动态清零”政策后 SARS-CoV-2 奥密克戎 BF.7 的传播动力学。
Nat Med. 2023 Mar;29(3):579-582. doi: 10.1038/s41591-023-02212-y. Epub 2023 Jan 13.
3
COVID-19 emergencies around the globe: China's experience in controlling COVID-19 and lessons learned.全球 COVID-19 紧急情况:中国控制 COVID-19 的经验和教训。
Int J Qual Health Care. 2021 Feb 20;33(1). doi: 10.1093/intqhc/mzaa143.
4
China's zero-COVID strategy: what happens next?中国的动态清零政策:接下来会怎样?
Nature. 2022 Feb;602(7895):15-16. doi: 10.1038/d41586-022-00191-7.
5
China's global engagement to fight the novel coronavirus pandemic.中国参与全球抗疫斗争。
Glob Health Res Policy. 2020 Oct 16;5:44. doi: 10.1186/s41256-020-00172-1. eCollection 2020.
6
Diagnostic strategy of SARS-CoV-2 for containment under China's zero-COVID-19 policy.中国“动态清零”政策下新型冠状病毒肺炎的诊断策略
J Infect. 2022 Jul;85(1):e7-e9. doi: 10.1016/j.jinf.2022.04.044. Epub 2022 May 1.
7
Omicron is bad but the global response is worse.奥密克戎毒株很糟糕,但全球应对措施更糟糕。
Nature. 2021 Dec;600(7888):190. doi: 10.1038/d41586-021-03616-x.
8
The application and implications of science and technology innovation in the management of education for Chinese students studying abroad in China in the epidemic era.疫情时代来华留学教育管理中科技创新的应用及启示。
PLoS One. 2024 Aug 16;19(8):e0306785. doi: 10.1371/journal.pone.0306785. eCollection 2024.
9
Development, Status Quo, and Challenges to China's Health Informatization During COVID-19: Evaluation and Recommendations.新冠疫情下中国卫生信息化的发展、现状与挑战:评估与建议。
J Med Internet Res. 2021 Jun 17;23(6):e27345. doi: 10.2196/27345.
10
Innovation alone won't end COVID-19.仅靠创新无法终结新冠疫情。
Nat Hum Behav. 2022 Feb;6(2):172-173. doi: 10.1038/s41562-022-01298-7.

引用本文的文献

1
So far, no novel SARS-CoV-2 variants from Beijing-and hopefully better scientific cooperation going forward.到目前为止,尚未发现来自北京的新型新冠病毒变异株——希望未来能有更好的科学合作。
Lancet. 2023 Feb 25;401(10377):621-622. doi: 10.1016/S0140-6736(23)00268-4. Epub 2023 Feb 8.
2
'Dynamic zero-COVID' policy and viral clearance during an omicron wave in Tianjin, China: a city-wide retrospective observational study.中国天津奥密克戎疫情期间的“动态清零”政策与病毒清除:全市回顾性观察研究。
BMJ Open. 2022 Dec 15;12(12):e066359. doi: 10.1136/bmjopen-2022-066359.
3
Willingness to pay for and willingness to vaccinate with the COVID-19 vaccine booster dose in China.
中国民众为新冠疫苗加强针支付费用的意愿及接种意愿。
Front Pharmacol. 2022 Sep 20;13:1013485. doi: 10.3389/fphar.2022.1013485. eCollection 2022.